Department of Animal Reproduction, Faculty of Veterinary Medicine, University of São Paulo, São Paulo, Brazil.
PLoS One. 2020 Jun 25;15(6):e0234714. doi: 10.1371/journal.pone.0234714. eCollection 2020.
As a consequence of a hormonal imbalance, Prostatic Hyperplasia (PH) is characterized by increased prostate volume, along with higher local angiogenesis and vascularization. Orchiectomy is the common treatment for dogs, however it is not an option for breeding animals. Thus, finasteride arises as the drug of choice for stud dogs. Therefore, the aim of this study was to evaluate the effects of orchiectomy or finasteride therapies on hormonal and vascular dynamics of PH dogs. Fifteen dogs, aged 6-13 years were assigned to: Untreated Group (dogs diagnosed with PH-n = 5), Finasteride treated group (PH dogs treated with finasteride-n = 5) and Orchiectomy treated group (PH dogs submitted to orchiectomy-n = 5). Evaluations were performed in a monthly interval (first day of treatment; after 30 and 60 days). Doppler ultrasonography was performed to measure prostatic volume, vascularization and hemodynamic profile of prostatic artery. Dihydrotestosterone, estrogen and testosterone concentrations were measured. At day 60, prostatic biopsy was performed for histological, immunohistochemical and qPCR analysis for VEGF-A expression. At day 60, vascularization score was higher in untreated compared to treated groups (finasteride and orchiectomy). Furthermore, VEGF-A expression was lower in the Orchiectomy Treated Group, but VEGF-A was immunohistochemically lower in both treated groups (finasteride and orchiectomy) compared to the Untreated Group. The efficiency of finasteride treatment in reducing clinical signs, prostate volume and vascularization appears to be similar to orchiectomy. In conclusion, both PH medical and surgical therapy lead to reduction in prostate dimension and VEGF-A expression and, consequently, lower local vascularization. However, orchiectomy promotes marked hormonal changes, which ultimately lead to prostate atrophy.
由于激素失衡，前列腺增生（PH）的特征是前列腺体积增加，同时伴有局部血管生成和血管化增加。去势是犬 PH 的常用治疗方法，但不适用于种用动物。因此，非那雄胺成为种用犬的首选药物。因此，本研究旨在评估去势或非那雄胺治疗对 PH 犬激素和血管动力学的影响。将 15 只年龄在 6-13 岁的犬分为：未治疗组（PH 犬 n = 5）、非那雄胺治疗组（PH 犬用非那雄胺治疗 n = 5）和去势治疗组（PH 犬行去势手术 n = 5）。每月评估一次（治疗的第一天；30 天和 60 天）。多普勒超声检查测量前列腺体积、前列腺动脉的血管化和血液动力学特征。测量二氢睾酮、雌激素和睾酮浓度。在第 60 天，对前列腺进行活检，进行组织学、免疫组织化学和 qPCR 分析，以检测 VEGF-A 的表达。第 60 天，未治疗组的血管化评分高于治疗组（非那雄胺和去势组）。此外，去势治疗组的 VEGF-A 表达较低，但非那雄胺和去势治疗组的 VEGF-A 免疫组织化学表达均低于未治疗组。非那雄胺治疗在减少临床症状、前列腺体积和血管化方面的效果似乎与去势相似。总之，PH 的药物和手术治疗都可减少前列腺体积和 VEGF-A 的表达，从而降低局部血管化。然而，去势会引起明显的激素变化，最终导致前列腺萎缩。
